Abstract
BackgroundDespite compelling preclinical data, agonistic anti-CD137 antibodies have been hampered by failure to delineate hepatotoxicity from efficacy in clinical studies.1 2 A new generation of both systemic and targeted CD137...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have